Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Intra-Cellular Therapies, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 288
- +15 vs. Q1 2023
- Shares held
- 84.4M
- +550.7K (+0.7%) vs. Q1 2023
- Total value
- $5.34B
- +$797.5M (+17.5%) vs. Q1 2023
- New holders
- 51
- 115 more added
- Sold out
- 36
- 78 more reduced
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ITCI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $2.54K |
| Q1 2026 | 1 | $2.54K |
| Q4 2025 | 1 | $2.54K |
| Q3 2025 | 1 | $2.54K |
| Q2 2025 | 4 | $4.15M |
| Q1 2025 | 395 | $13.6B |
| Q4 2024 | 387 | $8.08B |
| Q3 2024 | 356 | $7.12B |
| Q2 2024 | 376 | $6.62B |
| Q1 2024 | 346 | $6.15B |
| Q4 2023 | 335 | $6.42B |
| Q3 2023 | 294 | $4.54B |
| Q2 2023 | 288 | $5.34B |
| Q1 2023 | 274 | $4.55B |
| Q4 2022 | 283 | $4.41B |
| Q3 2022 | 274 | $3.89B |
| Q2 2022 | 266 | $4.65B |
| Q1 2022 | 241 | $4.94B |
| Q4 2021 | 208 | $3.60B |
| Q3 2021 | 181 | $2.56B |
| Q2 2021 | 187 | $2.74B |
| Q1 2021 | 170 | $2.30B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Intra-Cellular Therapies, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nomura Holdings Inc | 0 | $0 | 0.00% | −21,909−100.0% | Sold out |
| Banque Pictet & Cie SA | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| CenterBook Partners LP | 0 | $0 | 0.00% | −16,029−100.0% | Sold out |
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −15,627−100.0% | Sold out |
| Hussman Strategic Advisors, Inc. | 0 | $0 | 0.00% | −15,500−100.0% | Sold out |
| Maverick Capital LtdSuperinvestorMaverick Capital | 0 | $0 | 0.00% | −9,057−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −8,602−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −8,842−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −7,583−100.0% | Sold out |
| Campbell & CO Investment Adviser LLC | 0 | $0 | 0.00% | −6,962−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −6,876−100.0% | Sold out |
| Canada Pension Plan Investment Board | 0 | $0 | 0.00% | −6,700−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −5,085−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −4,527−100.0% | Sold out |
| Toroso Investments, LLC | 0 | $0 | 0.00% | −3,980−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −3,960−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −3,735−100.0% | Sold out |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −1,256−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −568−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −204−100.0% | Sold out |
| Itau Unibanco Holding S.A. | 0 | $0 | 0.00% | −151−100.0% | Sold out |
| Milestone Investment Advisors LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Mendota Financial Group, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Stonnington Group, LLC | – | – | – | – | Not filed |